美沙拉嗪联合固本益肠片对溃疡性结肠炎患者炎症因子及肠黏膜屏障功能的影响  

Effects of Mesalazine combined with Gubenyichang tablets on inflammatory factors and intestinal mucosal barrier function in UC patients

作　　者：秦芳芳[1] 郑长清[1] 张喆[1] QIN Fang-fang;ZHENG Chang-qing;ZHANG Zhe(Second Department of Digestive Medicine,Affiliated Shengjing Hospital of China Medical University,110022 Shenyang,Liaoning,China)

机构地区：[1]中国医科大学附属盛京医院第二消化内科,辽宁沈阳110022

出　　处：《临床消化病杂志》2020年第3期168-171,共4页Chinese Journal of Clinical Gastroenterology

摘　　要：[目的]探讨美沙拉嗪联合固本益肠片对溃疡性结肠炎(ulcerative colitis,UC)患者炎症因子及肠黏膜屏障功能的影响.[方法]入选80例UC患者为研究对象,根据患者对治疗方案的选择分为观察组(40例)和对照组(40例);观察组口服美沙拉嗪联合固本益肠片治疗,对照组单服美沙拉嗪治疗.观察2组治疗前后炎症因子、肠黏膜屏障功能、肠道菌群及中医证候积分的变化.[结果]治疗前2组患者炎症因子、肠黏膜屏障功能、肠道菌群及中医证候积分水平比较均差异无统计学意义(P>0.05).疗程结束后与治疗前比较,观察组INF-γ水平无明显变化,对照组INF-γ水平明显升高(P<0.05);2组IL-1p、IL-17、IL-23、D-乳酸、UAMY、DAO水平均较治疗前明显降低(P<0.05).与治疗前比较,疗程结束后2组肠球菌、大肠埃希菌明显减少,乳酸杆菌、双歧杆菌明显增加(P<0.05),各项中医证候积分明显降低(P<0.05);观察组治疗后各项指标变化水平均明显优于对照组(P<0.05).[结论]美沙拉嗪联合固本益肠片比单独使用美沙拉嗪治疗UC效果更好,安全性更高,值得临床推广应用.[Objective]To investigate the effects of mesalazine combined with Gubenyichang tablets on inflammatory factors and intestinal mucosal barrier function in patients with ulcerative colitis(UC).[Methods]Eighty patients with UC admitted to our hospital from April 2016 to April 2018 were selected as the research objects.According to the choice of treatment plan,they were divided into observation group(40 cases)and control group(40 cases).The observation group was treated with oral mesalazine combined with Gubenyichang tablet,while the control group was treated with single mesalazine,and the changes of inflammatory factors,intestinal mucosal barrier function,intestinal flora and TCM syndrome scores were ob-served before and after treatment.[Results]There were no significant differences in inflammatory factors,intestinal mucosal barrier function,intestinal flora and TCM syndrome scores between the two groups before treatment(P>0.05).There was no significant change in INF-Y levels in the observation group after the treatment.The levels of INF-γin the control group were significantly increased(P<0.05),and the levels of IL-1β,IL-17 and IL-23 were significantly decreased(P<0.05).The levels of D-lactic acid,UAMY and DAO in the two groups decreased significantly after treatment(P<0.05).After the treatment,Enterococcus and Escherichia coli in the two groups decreased significantly,while Lactobacillus and bifidobacteria in-creased significantly(P<0.05).After the treatment,the TCM syndrome scores of the two groups were significantly lower(P<0.05).The changes of each index in the observation group were significantly better than those in the control group(P<0.05).[Conclusion]Mesalazine combined with Gubenyichang tablets is better and safer than mesalazine alone in the treatment of UC,which is worthy of clinical application.

关 键 词：结肠炎 溃疡性 美沙拉嗪 固本益肠片 炎症因子 肠黏膜屏障功能 

分 类 号：R574.62[医药卫生—消化系统]